Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ATACK
- Development stage
- Preclinical
- Lead developer
- Biotherapy International
- Modality
- TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Allogeneic iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ATACK (Allogeneic Targeted Activated Cancer Killer cells) is an allogeneic cell therapy developed by the International Institute of Biotherapy (also known as Biotherapy International). The therapy utilizes intentionally mismatched immune effector cells, including T cells, Natural Killer (NK) cells, and Natural Killer T (NKT) cells, derived from healthy donors. These cells are activated and targeted against cancer cells, particularly in patients who have failed conventional anti-cancer modalities. The mechanism of action involves a rejection-like immune response against the tumor. In some protocols, monoclonal antibodies are used to enhance targeting against specific overexpressed antigens on the surface of cancer cells. It has shown effectiveness in treating hematologic malignancies such as acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), non-Hodgkin's lymphoma (NHL), and multiple myeloma, particularly when administered at the stage of minimal residual disease (MRD).
- Other names
- Allogeneic Targeted Activated Cancer Killer cellsATACK cells
Beyond the preview
Go deeper on ATACK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ATACK.